TAIPEI — Taiwan’s government on Monday approved the emergency use and production of Medigen Vaccine Biologics Corp’s COVID-19 vaccine candidate, a major step in the island’s plans to develop its own vaccines to protect against the coronavirus.
The vaccine candidate has yet to finish clinical trials and no efficacy data is available, but Taiwan’s health ministry said studies so far have shown that antibodies created by the shot have been “no worse than” those created by AstraZeneca’s vaccine.
Taiwan-based Medigen said last month it was seeking a speedy emergency use authorization, or EUA, from the government for its vaccine candidate after safely completing Phase II t…
Keep on reading: Taiwan approves Medigen’s COVID-19 vaccine candidate